Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Worksho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
| Cellectar Biosciences, Inc. (NASDAQ: CLRB) | Delayed: 1.23 +0.02 (1.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.21 | 52 Week High | $6.03 | |||
| Open | $1.23 | 52 Week Low | $0.41 | |||
| Day High | $1.26 | P/E | N/A | |||
| Day Low | $1.18 | EPS | $0.00 | |||
| Volume | 45,514 | |||||
